FLOW CYTOMETRY AND CELLULAR IMAGING FACILITY (FCCIF) The Flow Cytometry and Cellular Imaging Facility (FCCIF) was established to provide access to state-of-the-art equipment for single-cell analysis and isolation, and to provide expertise in cell sorting, analytical flow cytometry, cellular imaging, and custom monoclonal antibody-fluorochrome conjugations. Core personnel are available to design and execute experiments and analyze the results using a variety of commercially available or Core- designed custom software packages. The Core is comprised of 2 independently managed sites: one on the North Campus (NC) and the other on the South Campus (SC). Dr. Michael Andreeff is the director of the FCCIF; Dr. Jared K. Burks is co-director of the NC site, and Dr. Karen Clise-Dwyer is co-director of the SC laboratory. The FCCIF-NC specializes in fluorescence-activated cell sorting, sorting, mass cytometry (CyTOF -cytometry by time of flight), and cellular imaging. A major investment has been made in mass cytometry; the Core is now part of The University of Texas System Proteomics Network and has 2 CyTOFs and a Hyperion mass cytometer funded by both MD Anderson Cancer Center and The University of Texas System. The FCCIF-SC specializes in highly multi-parametric fluorescence-based analytical flow cytometry and cell sorting, and offers imaging flow cytometry using an Amnis ImageStream system. Over the past 6 years, the institution has provided $695,000 in renovations and $4,512,156 in funds for capital equipment. The FCCIF now uses 27 major instrument systems (NC: 14; SC: 13) and over the past 6 years has provided service to 404 cancer center members in support of all 16 CCSG programs as well as numerous MD Anderson Moon Shot programs and platforms, P01s, R01s, and P50 SPOREs. Cancer center members with peer-reviewed funding account for 92% of use, and 28% ($467,180) of the total Core budget is requested from the CCSG. In the current grant cycle, the FCCIF has provided 95,375 hours of service, and grant Yr42 had a 35% increase in use over that in Yr37 and a 63% increase over the average in the previous grant period. Since the previous grant period, the FCCIF has supported 589 publications, with 421 (71%) appearing in journals with IF >5 and 167 (28%) in journals with IF >10, including Science, Nature, Nat Med, Nat Immunol, Cell, Immunity, Cancer Cell, and Cell Stem Cell. The FCCIF specific aims are:
Aim 1) Collaboration: To provide the MD Anderson research community with unparalleled expertise to address important research hypotheses using robust, state-of-the-art flow cytometry and cellular imaging techniques;
Aim 2) Innovation: To develop and validate new methods in the fields of cytometry, cell sorting, and cellular imaging;
and Aim 3) Education: To educate users in applicable methodology and best practices in data collection and analysis to facilitate research rigor and reproducibility.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-43S1
Application #
9997850
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Yin, Guosheng; Chen, Nan; Lee, J Jack (2018) Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-event Endpoint. Stat Biosci 10:420-438
Nong, Jingying; Gong, Yuhua; Guan, Yanfang et al. (2018) Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nat Commun 9:3114
Brown, Justin C; Rickels, Michael R; Troxel, Andrea B et al. (2018) Dose-response effects of exercise on insulin among colon cancer survivors. Endocr Relat Cancer 25:11-19
Vakil, Erik; Jimenez, Carlos A; Faiz, Saadia A (2018) Pleural effusions in hematologic malignancies and their management with indwelling pleural catheters. Curr Opin Pulm Med 24:384-391
Yedururi, Sireesha; Chawla, Sumedha; Amini, Behrang et al. (2018) Tumor thrombus in the large veins draining primary pelvic osteosarcoma on cross sectional imaging. Eur J Radiol 105:49-55
Farinholt, Paige; Park, Minjeong; Guo, Ying et al. (2018) A Comparison of the Accuracy of Clinician Prediction of Survival Versus the Palliative Prognostic Index. J Pain Symptom Manage 55:792-797
Oh, Sang Cheul; Sohn, Bo Hwa; Cheong, Jae-Ho et al. (2018) Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun 9:1777
Yang, Yi; Li, Chia-Wei; Chan, Li-Chuan et al. (2018) Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res 28:862-864
Hui, David; Hess, Kenneth; Dibaj, Seyedeh S et al. (2018) The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium. Cancer 124:2246-2252
LeBleu, Valerie S; Kalluri, Raghu (2018) A peek into cancer-associated fibroblasts: origins, functions and translational impact. Dis Model Mech 11:

Showing the most recent 10 out of 12418 publications